title: [Advances in leukemia inhibitors targeting PI3K/AKT/mTOR pathway].
authors.affiliation: Institute of Hematology and Blood Disease Hospital, CAMS/PUMC, State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
authors.forename: Le
authors.initials: L
authors.lastname: Wang
authors.affiliation: Institute of Hematology and Blood Disease Hospital, CAMS/PUMC, State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
authors.forename: Yajing
authors.initials: Y
authors.lastname: Chu
authors.affiliation: Institute of Hematology and Blood Disease Hospital, CAMS/PUMC, State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
authors.forename: Tao
authors.initials: T
authors.lastname: Cheng
authors.affiliation: Institute of Hematology and Blood Disease Hospital, CAMS/PUMC, State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
authors.forename: Weiping
authors.initials: W
authors.lastname: Yuan
mesh_terms: D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000081082:Phosphoinositide-3 Kinase Inhibitors; C546842:MTOR protein, human; D051057:Proto-Oncogene Proteins c-akt; D058570:TOR Serine-Threonine Kinases